This study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of QAX576 in patients with idiopathic pulmonary fibrosis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
To evaluate the safety, tolerability, and effect on lung function of multiple intravenous doses of QAX576 in patients with IPF
Timeframe: 1 year
Change in forced vital capacity (FVC) at 52 weeks as compared to baseline
Timeframe: 1 year
Safety and tolerability of QAX576.
Timeframe: 1 year